ODC1 and glioma: ODC blockade with Difluoromethylornithine (DFMO) remains in clinical trials for glioma (NCT02796261); though upregulation of polyamine transporters may mediate metabolic compensation leading to improved survival with dual blockade of ODC and polyamine transporters (via AMXT-1501), in preclinical models of diffuse midline gliomas and other cancers60,61.